Literature DB >> 15037624

A mutation in human topoisomerase II alpha whose expression is lethal in DNA repair-deficient yeast cells.

Jerrylaine V Walker1, Karin C Nitiss, Lars H Jensen, Christopher Mayne, Tao Hu, Peter B Jensen, Maxwell Sehested, Tao Hsieh, John L Nitiss.   

Abstract

Type II DNA topoisomerases are ATP-dependent enzymes that catalyze alterations in DNA topology. These enzymes are important targets of a variety of anti-bacterial and anti-cancer agents. We identified a mutation in human topoisomerase II alpha, changing aspartic acid 48 to asparagine, that has the unique property of failing to transform yeast cells deficient in recombinational repair. In repair-proficient yeast strains, the Asp-48 --> Asn mutant can be expressed and complements a temperature-sensitive top2 mutation. Purified Asp-48 --> Asn Top2alpha has relaxation and decatenation activity similar to the wild type enzyme, but the purified protein exhibits several biochemical alterations compared with the wild type enzyme. The mutant enzyme binds both covalently closed and linear DNA with greater avidity than the wild type enzyme. hTop2alpha(Asp-48 --> Asn) also exhibited elevated levels of drug-independent cleavage compared with the wild type enzyme. The enzyme did not show altered sensitivity to bisdioxopiperazines nor did it form stable closed clamps in the absence of ATP, although the enzyme did form elevated levels of closed clamps in the presence of a non-hydrolyzable ATP analog compared with the wild type enzyme. We suggest that the lethality exhibited by the mutant is likely because of its enhanced drug-independent cleavage, and we propose that alterations in the ATP binding domain of the enzyme are capable of altering the interactions of the enzyme with DNA. This mutant enzyme also serves as a new model for understanding the action of drugs targeting topoisomerase II.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037624     DOI: 10.1074/jbc.M312314200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.

Authors:  Nicole Stantial; Anna Rogojina; Matthew Gilbertson; Yilun Sun; Hannah Miles; Samantha Shaltz; James Berger; Karin C Nitiss; Sue Jinks-Robertson; John L Nitiss
Journal:  Proc Natl Acad Sci U S A       Date:  2020-10-12       Impact factor: 11.205

2.  A syngeneic variance library for functional annotation of human variation: application to BRCA2.

Authors:  Tomas Hucl; Carlo Rago; Eike Gallmeier; Jonathan R Brody; Myriam Gorospe; Scott E Kern
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

3.  Isolation and characterization of mAMSA-hypersensitive mutants. Cytotoxicity of Top2 covalent complexes containing DNA single strand breaks.

Authors:  Anna T Rogojina; John L Nitiss
Journal:  J Biol Chem       Date:  2008-08-22       Impact factor: 5.157

4.  PIASy-dependent SUMOylation regulates DNA topoisomerase IIalpha activity.

Authors:  Hyunju Ryu; Maiko Furuta; Donald Kirkpatrick; Steven P Gygi; Yoshiaki Azuma
Journal:  J Cell Biol       Date:  2010-11-15       Impact factor: 10.539

5.  Real-time detection of DNA topological changes with a fluorescently labeled cruciform.

Authors:  Kevin M Jude; Abbey Hartland; James M Berger
Journal:  Nucleic Acids Res       Date:  2013-05-16       Impact factor: 16.971

6.  Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers.

Authors:  Arnoud Boot; Mo Liu; Nicole Stantial; Viraj Shah; Willie Yu; Karin C Nitiss; John L Nitiss; Sue Jinks-Robertson; Steven G Rozen
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 12.779

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.